<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d2d333c7-76ee-463d-afeb-c2a7217c29a1"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use LEVOTHYROXINE SODIUM TABLETS safely and effectively. See full prescribing information for LEVOTHYROXINE SODIUM TABLETS.<br/>
      <br/>LEVOTHYROXINE SODIUM tablets, for oral use<br/>Initial U.S. Approval: 2002</title>
   <effectiveTime value="20250522"/>
   <setId root="faaa1123-7515-46c2-abbb-b0615540c8cf"/>
   <versionNumber value="7"/>
   <author>
      <assignedEntity>
         <representedOrganization>
            <id extension="830016429" root="1.3.6.1.4.1.519.1"/>
            <name>A-S Medication Solutions</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="830016429" root="1.3.6.1.4.1.519.1"/>
                        <name>A-S Medication Solutions</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" displayName="RELABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50090-4947" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="REPACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50090-4947" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="7d26a65c-2268-46b5-b043-625d909af100"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250319"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50090-4947" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levothyroxine Sodium</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Levothyroxine Sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="68180-965" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator value="0.025" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9J765S329G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVOTHYROXINE SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q51BO43MG4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVOTHYROXINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="054I36CPMN" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVOTHYROXINE SODIUM ANHYDROUS</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>KI5</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8MDF5V39QO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BICARBONATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50090-4947-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20200302"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50090-4947-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20200302"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA209713" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190320"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORANGE">
                              <originalText>Peach</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="6" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="2"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">L15</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID234">
               <id root="4091c4cb-da69-4edc-83e7-9d1c83d798d6"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title>RECENT MAJOR CHANGES</title>
               <effectiveTime value="20240229"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dosage and Administration, Important Considerations for Dosing (<linkHtml href="#ID98">2.2</linkHtml>)                                2/2024</paragraph>
                        <paragraph>Dosage and Administration, Monitoring TSH and/or Thyroxine (T4) Levels (<linkHtml href="#ID104">2.4</linkHtml>)                2/2024</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID83">
               <id root="2f6a9f54-303d-40a2-b4cd-611f884136c4"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Thyroid hormones, including levothyroxine sodium tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects<content styleCode="italics"> [see Adverse Reactions (6), Drug Interactions (<linkHtml href="#ID156">7.7</linkHtml>), and Overdosage (<linkHtml href="#ID180">10</linkHtml>)]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250319"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID87" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Thyroid hormones, including levothyroxine sodium tablet, should not be used for the treatment of obesity or for weight loss.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Doses beyond the range of daily hormonal requirements may produce serious or even life-threatening manifestations of toxicity (<linkHtml href="#ID132">6</linkHtml>, <linkHtml href="#ID178">10</linkHtml>).</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID88">
               <id root="11c94aea-adc7-42d5-b9d6-579dc19c3359"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Hypothyroidism</content>
                  </paragraph>
                  <paragraph>Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression</content>
                  </paragraph>
                  <paragraph>Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Limitations of Use</content>
                  </paragraph>
                  <list listType="unordered" ID="ID90" styleCode="Disc">
                     <item>Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID120">5.1</linkHtml>)]</content>.</item>
                     <item>Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.</item>
                  </list>
               </text>
               <effectiveTime value="20240229"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Levothyroxine sodium tablet is a L-thyroxine (T4) indicated in adult and pediatric patients, including neonates, for:</paragraph>
                        <list listType="unordered" ID="ID93" styleCode="Disc">
                           <item>Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. (<linkHtml href="#ID88">1</linkHtml>)</item>
                           <item>Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. (<linkHtml href="#ID88">1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <list listType="unordered" ID="ID237" styleCode="Disc">
                           <item>Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients.</item>
                           <item>Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID95">
               <id root="af89cba5-b3bf-4700-8bde-48593d39dca9"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20240313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID107" styleCode="Disc">
                           <item>Administer once daily, preferably on an empty stomach, one-half to one hour before breakfast. (<linkHtml href="#ID96">2.1</linkHtml>)</item>
                           <item>Administer at least 4 hours before or after drugs that are known to interfere with absorption. (<linkHtml href="#ID96">2.1</linkHtml>)</item>
                           <item>Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. (<linkHtml href="#ID96">2.1</linkHtml>)</item>
                           <item>Advise patients to stop biotin and biotin-containing supplements at least 2 days before assessing TSH and/or T4 levels. (<linkHtml href="#ID98">2.2</linkHtml>)</item>
                           <item>Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medications. Peak therapeutic effect may not be attained for 4 to 6 weeks. (<linkHtml href="#ID98">2.2</linkHtml>)</item>
                           <item>See full prescribing information for dosing in specific patient populations. (<linkHtml href="#ID100">2.3</linkHtml>)</item>
                           <item>Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status. (<linkHtml href="#ID104">2.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID96">
                     <id root="b5f77f55-7783-4e8a-9bfe-ca63a71baa0a"/>
                     <title>2.1 Important Administration Instructions</title>
                     <text>
                        <paragraph>Administer levothyroxine sodium tablets as a single daily dose, on an empty stomach, one-half to one hour before breakfast.</paragraph>
                        <paragraph>Administer levothyroxine sodium tablets at least 4 hours before or after drugs known to interfere with levothyroxine sodium tablets absorption <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID139">7.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Evaluate the need for dosage adjustments when regularly administering within one hour of certain foods that may affect levothyroxine sodium tablets absorption <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID98">2.2 </linkHtml>and <linkHtml href="#ID100">2.3</linkHtml>), Drug Interactions (<linkHtml href="#ID160">7.9</linkHtml>), and Clinical Pharmacology (<linkHtml href="#ID190">12.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>Administer levothyroxine sodium tablets to pediatric patients who cannot swallow intact tablets by crushing the tablet, suspending the freshly crushed tablet in a small amount (5 to 10 mL) of water and immediately administering the suspension by spoon or dropper. Ensure the patient ingests the full amount of the suspension. Do not store the suspension. Do not administer in foods that decrease absorption of levothyroxine sodium tablets, such as soybean-based infant formula <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID160">7.9</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="ID98">
                     <id root="6751ac6a-8af0-4e59-9d3c-6a90873dcd2a"/>
                     <title>2.2 Important Considerations for Dosing</title>
                     <text>
                        <paragraph>The dosage of levothyroxine sodium tablets for hypothyroidism or pituitary TSH suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food and the specific nature of the condition being treated <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID100">2.3</linkHtml>), Warnings and Precautions (<linkHtml href="#ID117">5</linkHtml>), and Drug Interactions (<linkHtml href="#ID138">7</linkHtml>)]</content>. Dosing must be individualized to account for these factors and dosage adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID104">2.4</linkHtml>)]</content>. </paragraph>
                        <paragraph>For adult patients with primary hypothyroidism, titrate until the patient is clinically euthyroid and the serum TSH returns to normal <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID100">2.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>For secondary or tertiary hypothyroidism, serum TSH is not a reliable measure of levothyroxine sodium tablets dosage adequacy and should not be used to monitor therapy. Use the serum free-T4 level to titrate levothyroxine sodium tablets dosing until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range<content styleCode="italics"> [see Dosage and Administration (<linkHtml href="#ID100">2.3</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange"> Inquire whether patients are taking biotin or biotin-containing supplements. If so, advise them to stop biotin supplementation at least 2 days before assessing TSH and/or T4 levels <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID104">2.4</linkHtml>) and Drug Interactions (<linkHtml href="#ID162">7.10</linkHtml>)].</content>
                           </content>
                        </paragraph>
                        <paragraph>The peak therapeutic effect of a given dose of levothyroxine sodium tablets may not be attained for 4 to 6 weeks.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="ID100">
                     <id root="1c21690a-7e0e-4220-bd77-1d7e7c8c841c"/>
                     <title>2.3 Recommended Dosage and Titration</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Primary, Secondary, and Tertiary Hypothyroidism in Adults</content>
                        </paragraph>
                        <paragraph>The recommended starting daily dosage of levothyroxine sodium tablets in adults with primary, secondary, or tertiary hypothyroidism is based on age and comorbid cardiac conditions, as described in Table 1. For patients at risk of atrial fibrillation or patients with underlying cardiac disease, start with a lower dosage and titrate the dosage more slowly to avoid exacerbation of cardiac symptoms. Dosage titration is based on serum TSH or free-T4 <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID98">2.2</linkHtml>)].</content>
                        </paragraph>
                        <table width="0" styleCode="Noautorules">
                           <caption>  Table 1. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Adults* </caption>
                           <col width="180"/>
                           <col width="204"/>
                           <col width="240"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph>* Dosages greater than 200 mcg/day are seldom required. An inadequate response to daily dosages greater than 300 mcg/day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID96">2.1</linkHtml>) and Drug Interactions (<linkHtml href="#ID138">7</linkHtml>)].</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Patient Population</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Starting Dosage</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Dosage Titration Based on   Serum TSH or Free-T4</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Adults diagnosed with hypothyroidism<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left"> Full replacement dose is 1.6 mcg/kg/day. Some patients require a lower starting dose.<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left"> Titrate dosage by 12.5 to 25 mcg increments every 4 to 6 weeks, as needed until the patient is euthyroid.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Adults at risk for atrial fibrillation or with underlying cardiac disease<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left"> Lower starting dose (less than 1.6 mcg/kg/day)<br/>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Rrule" align="left"> Titrate dosage every 6 to 8 weeks, as needed until the patient is euthyroid.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Geriatric patients<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left"> Lower starting dose (less than 1.6 mcg/kg/day)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> <content styleCode="italics">Primary, Secondary and Tertiary Hypothyroidism in Pediatric Patients</content>
                        </paragraph>
                        <paragraph>The recommended starting daily dosage of levothyroxine sodium tablets in pediatric patients with primary, secondary, or tertiary hypothyroidism is based on body weight and changes with age as described in Table 2. Titrate the dosage (every 2 weeks) as needed based on serum TSH or free-T4 until the patient is euthyroid <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID98">2.2</linkHtml>)]</content>.</paragraph>
                        <table width="626" styleCode="Noautorules">
                           <caption>  Table 2. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Pediatric Patients </caption>
                           <col width="319"/>
                           <col width="307"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="2">
                                    <paragraph>
                                       <content styleCode="italics">
                                          <sup>a </sup>
                                       </content> Adjust dosage based on clinical response and laboratory parameters <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID104">2.4</linkHtml>) and Use in Specific Populations (<linkHtml href="#ID172">8.4</linkHtml>)].</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Age</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Starting Daily Dosage Per Kg Body Weight<sup>a</sup>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> 0 to 3 months<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10 to 15 mcg/kg/day<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> 3 to 6 months<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8 to 10 mcg/kg/day<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> 6 to 12 months<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6 to 8 mcg/kg/day<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> 1 to 5 years<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5 to 6 mcg/kg/day<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> 6 to 12 years<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4 to 5 mcg/kg/day<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> Greater than 12 years but growth and puberty incomplete<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2 to 3 mcg/kg/day<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> Growth and puberty complete<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1.6 mcg/kg/day<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients from Birth to 3 Months of Age at Risk for Cardiac Failure</content>
                        </paragraph>
                        <paragraph>Start at a lower starting dosage and increase the dosage every 4 to 6 weeks as needed based on clinical and laboratory response.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients at Risk for Hyperactivity</content>
                        </paragraph>
                        <paragraph>To minimize the risk of hyperactivity, start at one-fourth the recommended full replacement dosage, and increase on a weekly basis by one-fourth the full recommended replacement dosage until the full recommended replacement dosage is reached.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypothyroidism in Pregnant Patients</content>
                        </paragraph>
                        <paragraph>For pregnant patients with pre-existing hypothyroidism, measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at minimum, during each trimester of pregnancy. In pregnant patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. </paragraph>
                        <paragraph>The recommended daily dosage of levothyroxine sodium tablets in pregnant patients is described in Table 3.</paragraph>
                        <table width="0" styleCode="Noautorules">
                           <caption>  Table 3. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Pregnant Patients </caption>
                           <col width="205"/>
                           <col width="198"/>
                           <col width="229"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Patient Population</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Starting Dosage</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Dose Adjustment and   Titration</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Pre-existing primary hypothyroidism with serum TSH above normal trimester- specific range<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left"> Pre-pregnancy dosage may increase during pregnancy<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left"> Increase levothyroxine sodium tablet dosage by 12.5 to 25 mcg per day. Monitor TSH every 4 weeks until a stable dose is reached and serum TSH is within normal trimester-specific range. Reduce levothyroxine sodium tablet dosage to pre-pregnancy levels immediately after delivery. Monitor serum TSH 4 to 8 weeks postpartum.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> New onset hypothyroidism (TSH ≥ 10 mIU per liter)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left"> 1.6 mcg/kg/day<br/>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Rrule" align="left"> Monitor serum TSH every 4 weeks and adjust levothyroxine sodium tablet dosage until serum TSH is within normal trimester-specific range.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> New onset hypothyroidism (TSH &lt; 10 mIU per liter)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left"> 1.0 mcg/kg/day<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">TSH Suppression in Well-differentiated Thyroid Cancer in Adult and Pediatric Patients</content>
                        </paragraph>
                        <paragraph>The levothyroxine sodium tablets dosage is based on the target level of TSH suppression for the stage and clinical status of thyroid cancer.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="ID104">
                     <id root="8fd925f3-c85b-4fa6-8560-4f0d1596445e"/>
                     <title>2.4 Monitoring TSH and/or Thyroxine (T4) Levels</title>
                     <text>
                        <paragraph>Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation. </paragraph>
                        <paragraph>
                           <content styleCode="xmChange"> Biotin supplementation may interfere with immunoassays for TSH, T4, and T3, resulting in erroneous thyroid hormone test results. Stop biotin and biotin-containing supplements for at least 2 days before assessing TSH and/or T4 levels <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID162">7.10</linkHtml>)].</content>
                           </content>
                        </paragraph>
                        <paragraph>Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of levothyroxine sodium tablets may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Adults</content>
                        </paragraph>
                        <paragraph>In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dosage. In patients on a stable and appropriate replacement dosage, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient's clinical status.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>In patients with hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T4. Monitor TSH and total or free-T4 in pediatric patients as follows: 2 and 4 weeks after the initiation of treatment, 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dosage stabilization until growth is completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals.</paragraph>
                        <paragraph>The general aim of therapy is to normalize the serum TSH level. TSH may not normalize in some patients due to in utero hypothyroidism causing a resetting of pituitary-thyroid feedback. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of levothyroxine sodium tablets therapy and/or of the serum TSH to decrease below 20 mIU per liter within 4 weeks may indicate the patient is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of levothyroxine sodium tablets <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID238">5.1</linkHtml>) and Use in Specific Populations (<linkHtml href="#ID172">8.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Secondary and Tertiary Hypothyroidism</content>
                        </paragraph>
                        <paragraph>Monitor serum free-T4 levels and maintain in the upper half of the normal range in these patients.</paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID108">
               <id root="2c19c0c4-4bf1-4f90-9dc8-3531e2f9ab3c"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Levothyroxine sodium tablets USP are round, colored, scored and debossed with following debossing details on one side and break-line on other side. They are available as follows (Table 4)</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <caption>  Table 4: Levothyroxine Sodium Tablet Strengths and Identifying Features </caption>
                     <col width="30%"/>
                     <col width="36%"/>
                     <col width="33%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Tablet Strength</content>
                              <br/>
                           </td>
                           <td styleCode=" Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Tablet Color/Shape</content>
                              <br/>
                           </td>
                           <td styleCode=" Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Debossing Details</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> 25 mcg<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Peach/Round<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> L15<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> 50 mcg<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> White/Round<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> L16<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> 75 mcg<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Violet/Round<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> L17<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> 88 mcg<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Olive/Round<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> L19<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> 100 mcg<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Yellow/Round<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> L20<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> 112 mcg<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Rose/Round<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> L21<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> 125 mcg<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Tan/Round<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> L22<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> 137 mcg<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Turquoise/Round<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> L23<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> 150 mcg<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Blue/Round<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> L24<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> 175 mcg<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Lilac/Round<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> L25<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> 200 mcg<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Pink/Round<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> L26<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> 300 mcg<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Green/Round<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> L27<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20221203"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, and 300 mcg (<linkHtml href="#ID108">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID113">
               <id root="b47d26bf-9f7d-45f9-ae10-226c0aaf2508"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID122">5.4</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20240229"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID116" styleCode="Disc">
                           <item>Uncorrected adrenal insufficiency. (<linkHtml href="#ID113">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID117">
               <id root="c377a9a5-9153-4024-9081-a61d52409eca"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID131" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Serious risks related to overtreatment or undertreatment with levothyroxine sodium tablet</content>: Titrate the dose of levothyroxine sodium tablet carefully and monitor response to titration. (<linkHtml href="#ID116">5.1</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease:</content>Initiate levothyroxine sodium tablet at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation. (<linkHtml href="#ID100">2.3</linkHtml>, <linkHtml href="#ID120">5.2</linkHtml>, <linkHtml href="#ID174">8.5</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Myxedema coma: </content>Do not use oral thyroid hormone drug products to treat myxedema coma. (<linkHtml href="#ID122">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Acute adrenal crisis in patients with concomitant adrenal insufficiency:</content>Treat with replacement glucocorticoids prior to initiation of levothyroxine sodium tablet treatment. (<linkHtml href="#ID124">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Worsening of diabetic control: </content>Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy. (<linkHtml href="#ID126">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Decreased bone mineral density associated with thyroid hormone over-replacement: </content>Over-replacement can increase bone resorption and decrease bone mineral density. Give the lowest effective dose. (<linkHtml href="#ID128">5.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID238">
                     <id root="7052bff6-8a60-4ca9-8d52-d128ac5a8e64"/>
                     <title>5.1 Serious Risks Related to Overtreatment or Undertreatment with Levothyroxine sodium tablets</title>
                     <text>
                        <paragraph>Levothyroxine sodium tablet has a narrow therapeutic index. Overtreatment or undertreatment with Levothyroxine sodium tablets may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, gastrointestinal function, and glucose and lipid metabolism in adult or pediatric patients.</paragraph>
                        <paragraph>In pediatric patients with congenital and acquired hypothyroidism, undertreatment may adversely</paragraph>
                        <paragraph>affect cognitive development and linear growth, and overtreatment is associated with craniosynostosis and acceleration of bone age <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID172">8.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>Titrate the dose of Levothyroxine sodium tablets carefully and monitor response to titration to avoid these effects <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID104">2.4</linkHtml>)]</content>. Consider the potential for food or drug interactions and adjust the administration or dosage of Levothyroxine sodium tablets as needed <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID96">2.1</linkHtml>), Drug Interactions (<linkHtml href="#ID139">7.1</linkHtml>), and Clinical Pharmacology (<linkHtml href="#ID190">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="ID118">
                     <id root="2c18ba4e-3f7d-4e57-aeb9-d0eaf8fc17ae"/>
                     <title>5.2 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease</title>
                     <text>
                        <paragraph>Over-treatment with levothyroxine may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. Initiate levothyroxine sodium tablets therapy in this population at lower doses than those recommended in younger individuals or in patients without cardiac disease <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID100">2.3</linkHtml>) and Use in Specific Populations (<linkHtml href="#ID174">8.5</linkHtml>)]</content>.</paragraph>
                        <paragraph>Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive levothyroxine sodium tablets therapy. Monitor patients receiving concomitant levothyroxine sodium tablets and sympathomimetic agents for signs and symptoms of coronary insufficiency.</paragraph>
                        <paragraph>If cardiac symptoms develop or worsen, reduce the levothyroxine sodium tablets dose or withhold for one week and restart at a lower dose.</paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID120">
                     <id root="5b6522b8-4e71-484b-b1b1-1bad93add3b1"/>
                     <title>5.3 Myxedema Coma</title>
                     <text>
                        <paragraph>Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Use of oral thyroid hormone drug products is not recommended to treat myxedema coma. Administer thyroid hormone products formulated for intravenous administration to treat myxedema coma.</paragraph>
                     </text>
                     <effectiveTime value="20221203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID122">
                     <id root="ff296fc7-f25b-402e-a21d-28fef8abd375"/>
                     <title>5.4 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency</title>
                     <text>
                        <paragraph>Thyroid hormone increases metabolic clearance of glucocorticoids. Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with levothyroxine sodium tablets <content styleCode="italics">[see Contraindications (<linkHtml href="#ID113">4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="ID126">
                     <id root="d3b95076-65a4-4e1b-8f33-b32f74dd0cc0"/>
                     <title>5.5 Worsening of Diabetic Control</title>
                     <text>
                        <paragraph>Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing levothyroxine sodium tablets <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID146">7.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="ID128">
                     <id root="039e5561-1c75-4706-9253-36756f8c1ea5"/>
                     <title>5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement</title>
                     <text>
                        <paragraph>Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase, and suppressed serum parathyroid hormone levels. Administer the minimum dose of levothyroxine sodium tablets that achieves the desired clinical and biochemical response to mitigate this risk.</paragraph>
                     </text>
                     <effectiveTime value="20240314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID132">
               <id root="5c1b8561-4c38-4595-a91a-dfc082e5db15"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Adverse reactions associated with levothyroxine sodium tablets therapy are primarily those of hyperthyroidism due to therapeutic overdosage <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID117">5</linkHtml>) and Overdosage (<linkHtml href="#ID178">10</linkHtml>)]</content>. They include the following:</paragraph>
                  <list listType="unordered" ID="ID134" styleCode="Disc">
                     <item>
                        <content styleCode="italics">General:</content>fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating</item>
                     <item>
                        <content styleCode="italics">Central nervous system:</content>headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia</item>
                     <item>
                        <content styleCode="italics">Musculoskeletal:</content>tremors, muscle weakness, muscle spasm</item>
                     <item>
                        <content styleCode="italics">Cardiovascular:</content>palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest</item>
                     <item>
                        <content styleCode="italics">Respiratory:</content>dyspnea</item>
                     <item>
                        <content styleCode="italics">Gastrointestinal:</content>diarrhea, vomiting, abdominal cramps, elevations in liver function tests</item>
                     <item>
                        <content styleCode="italics">Dermatologic:</content>hair loss, flushing, rash</item>
                     <item>
                        <content styleCode="italics">Endocrine:</content>decreased bone mineral density</item>
                     <item>
                        <content styleCode="italics">Reproductive:</content>menstrual irregularities, impaired fertility</item>
                  </list>
                  <paragraph>Seizures have been reported rarely with the institution of levothyroxine therapy.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Adverse Reactions in Pediatric Patients</content>
                  </paragraph>
                  <paragraph>Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants who have not undergone complete closure of the fontanelles, and in premature closure of the epiphyses in pediatric patients still experiencing growth with resultant compromised adult height.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness, and wheezing. Hypersensitivity to levothyroxine itself is not known to occur.</paragraph>
               </text>
               <effectiveTime value="20240229"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions associated with levothyroxine sodium tablets therapy are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash. (<linkHtml href="#ID132">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or</content> www.fda.gov/medwatch.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID138">
               <id root="edfdf5c6-01ab-46b6-b9ca-2c4637c39919"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20240229"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to levothyroxine sodium tablets. (<linkHtml href="#ID138">7</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID139">
                     <id root="7a38a5f5-d3f8-4a5b-b80b-3dfdbe855b98"/>
                     <title>7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics</title>
                     <text>
                        <paragraph>Many drugs can exert effects on thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to levothyroxine sodium tablets (Tables 5 to 8).</paragraph>
                        <table width="638" styleCode="Noautorules">
                           <caption>  Table 5. Drugs That May Decrease T4 Absorption (Hypothyroidism) </caption>
                           <col width="247"/>
                           <col width="391"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left"> Potential impact: Concurrent use may reduce the efficacy of levothyroxine sodium tablets by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Drug or Drug Class</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Effect</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Phosphate Binders<br/> (e.g., calcium carbonate, ferrous sulfate, sevelamer, lanthanum)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Phosphate binders may bind to levothyroxine. Administer levothyroxine sodium tablets at least 4 hours apart from these agents.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Orlistat<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Monitor patients treated concomitantly with orlistat and levothyroxine sodium tablets for changes in thyroid function.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Bile Acid Sequestrants<br/> (e.g., colesevelam, cholestyramine, colestipol)<br/> Ion Exchange Resins<br/> (e.g., Kayexalate)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption. Administer levothyroxine sodium tablets at least 4 hours prior to these drugs or monitor TSH levels.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Proton Pump Inhibitors<br/> Sucralfate<br/> Antacids<br/> (e.g., aluminum &amp; magnesium hydroxides, simethicone)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Gastric acidity is an essential requirement for adequate absorption of levothyroxine. Sucralfate, antacids and proton pump inhibitors may cause hypochlorhydria, affect intragastric pH, and reduce levothyroxine absorption. Monitor patients appropriately.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="726" styleCode="Noautorules">
                           <caption>  Table 6. Drugs That May Alter T4 and Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism) </caption>
                           <col width="363"/>
                           <col width="363"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Drug or Drug Class</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Effect</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Clofibrate<br/> Estrogen-containing oral contraceptives<br/> Estrogens (oral)<br/> Heroin / Methadone<br/> 5-Fluorouracil<br/> Mitotane<br/> Tamoxifen<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> These drugs may increase serum thyroxine-binding globulin (TBG) concentration.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Androgens / Anabolic Steroids<br/> Asparaginase <br/> Glucocorticoids <br/> Slow-Release Nicotinic Acid<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> These drugs may decrease serum TBG concentration.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left"> Potential impact (below): Administration of these agents with levothyroxine sodium tablets results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Salicylates (&gt; 2 g/day)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Other drugs: <br/> Carbamazepine <br/> Furosemide (&gt; 80 mg IV) <br/> Heparin <br/> Hydantoins<br/> Non-Steroidal Anti-inflammatory Drugs <br/> -Fenamates<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> These drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increase free T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="726" styleCode="Noautorules">
                           <caption>  Table 7. Drugs That May Alter Hepatic Metabolism of T4 (Hypothyroidism) </caption>
                           <col width="363"/>
                           <col width="363"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left"> Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased levothyroxine sodium tablets requirements.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Drug or Drug Class</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Effect</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Phenobarbital <br/> Rifampin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5'-diphospho-glucuronosyltransferase (UGT) and leads to lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="726" styleCode="Noautorules">
                           <caption>  Table 8. Drugs That May Decrease Conversion of T4 to T3 </caption>
                           <col width="363"/>
                           <col width="363"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left"> Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Drug or Drug Class</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Effect</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Beta-adrenergic antagonists (e.g., Propranolol &gt; 160 mg/day)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> In patients treated with large doses of propranolol (&gt; 160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when a hypothyroid patient is converted to the euthyroid state.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Glucocorticoids (e.g., Dexamethasone ≥ 4 mg/day)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (See above).<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Other drugs: <br/> Amiodarone<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20221203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID146">
                     <id root="29ff7067-ce57-44d7-a408-111f9a114f3c"/>
                     <title>7.2 Antidiabetic Therapy</title>
                     <text>
                        <paragraph>Addition of levothyroxine sodium tablets therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control, especially when thyroid therapy is started, changed, or discontinued <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID126">5.5</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="ID148">
                     <id root="3663b7bc-aa38-42aa-8678-b6b62c6d45af"/>
                     <title>7.3 Oral Anticoagulants</title>
                     <text>
                        <paragraph>Levothyroxine sodium tablet increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the levothyroxine sodium tablets dose is increased. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments.</paragraph>
                     </text>
                     <effectiveTime value="20221203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID150">
                     <id root="738be4b7-d956-430c-9882-1e2a0fc6d19a"/>
                     <title>7.4 Digitalis Glycosides</title>
                     <text>
                        <paragraph>Levothyroxine sodium tablets may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may decrease when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.</paragraph>
                     </text>
                     <effectiveTime value="20221203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID152">
                     <id root="bca633db-013b-4a28-9f2d-16474f5a874a"/>
                     <title>7.5 Antidepressant Therapy</title>
                     <text>
                        <paragraph>Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine sodium tablets may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. Levothyroxine sodium tablets may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on levothyroxine sodium tablets may result in increased levothyroxine sodium tablets requirements.</paragraph>
                     </text>
                     <effectiveTime value="20221203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID154">
                     <id root="883c3d29-2760-4e76-80d7-1b14a32a2060"/>
                     <title>7.6 Ketamine</title>
                     <text>
                        <paragraph>Concurrent use of ketamine and levothyroxine sodium tablets may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients.</paragraph>
                     </text>
                     <effectiveTime value="20221203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID156">
                     <id root="a83d410e-dca4-4bc4-8129-66c3c6e0e49b"/>
                     <title>7.7 Sympathomimetics</title>
                     <text>
                        <paragraph>Concurrent use of sympathomimetics and levothyroxine sodium tablets may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.</paragraph>
                     </text>
                     <effectiveTime value="20221203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID158">
                     <id root="531594cf-2095-4fa5-8d92-47d93773114e"/>
                     <title>7.8 Tyrosine-Kinase Inhibitors</title>
                     <text>
                        <paragraph>Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Closely monitor TSH levels in such patients.</paragraph>
                     </text>
                     <effectiveTime value="20221203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID160">
                     <id root="9303045f-8096-4626-a617-0a5948cd40e8"/>
                     <title>7.9 Drug-Food Interactions</title>
                     <text>
                        <paragraph>Consumption of certain foods may affect levothyroxine sodium tablets absorption thereby necessitating adjustments in dosing <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID96">2.1</linkHtml>)]</content>. Soybean flour, cottonseed meal, walnuts, and dietary fiber may bind and decrease the absorption of levothyroxine sodium tablets from the gastrointestinal tract. Grapefruit juice may delay the absorption of levothyroxine and reduce its bioavailability.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="ID162">
                     <id root="da7e7854-ec09-477e-ab12-4ea335201285"/>
                     <title>7.10 Drug-Laboratory Test Interactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Thyroxine-binding Globulin (TBG)</content>
                        </paragraph>
                        <paragraph>Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free-T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentration. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens, and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Biotin</content>
                        </paragraph>
                        <paragraph>Biotin supplementation is known to interfere with thyroid hormone immunoassays that are based on a biotin and streptavidin interaction, which may result in erroneous thyroid hormone test results. Stop biotin and biotin-containing supplements for at least 2 days prior to thyroid testing.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID167">
               <id root="41cdc29f-2a8b-4bcf-89ac-56559c9eb4d2"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240229"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Pregnancy may require the use of higher doses of levothyroxine sodium tablets. (<linkHtml href="#ID100">2.3</linkHtml>, <linkHtml href="#ID168">8.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID168">
                     <id root="fa097a4d-6c26-4d81-910c-1e6a3e03e1ac"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>The clinical experience, including data from postmarketing studies, in pregnant women treated with oral levothyroxine to maintain euthyroid state have not reported increased rates of major birth defects, miscarriages, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. Since TSH levels may increase during pregnancy, TSH should be monitored and levothyroxine sodium tablets dosage adjusted during pregnancy <content styleCode="italics">(see Clinical Considerations)</content>. Animal reproductive studies have not been conducted with levothyroxine sodium. Levothyroxine sodium tablets should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk</content>
                        </paragraph>
                        <paragraph>Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre-eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Dose Adjustments During Pregnancy and the Postpartum Period</content>
                        </paragraph>
                        <paragraph>Pregnancy may increase levothyroxine sodium tablets requirements. Serum TSH levels should be monitored and the levothyroxine sodium tablets dosage adjusted during pregnancy. Since postpartum TSH levels are similar to preconception values, the levothyroxine sodium tablets dosage should return to the pre-pregnancy dose immediately after delivery <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID100">2.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="ID170">
                     <id root="61055be6-cd76-4114-9e2f-bb1c41e17e8d"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Published studies report that levothyroxine is present in human milk following the administration of oral levothyroxine. No adverse effects on the breastfed infant have been reported and there is no information on the effects of levothyroxine on milk production. Adequate levothyroxine treatment during lactation may normalize milk production in hypothyroid lactating mothers with low milk supply. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for levothyroxine sodium tablets and any potential adverse effects on the breastfed infant from levothyroxine sodium tablets or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20221203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID172">
                     <id root="ccece842-13a7-4727-9c1f-2ee470a132b6"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Levothyroxine Sodium Tablets is indicated in patients from birth to less than 17 years of age:</paragraph>
                        <list listType="unordered" ID="ID244" styleCode="Disc">
                           <item>As a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.</item>
                           <item>As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.</item>
                        </list>
                        <paragraph>Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on cognitive development as well as on overall physical growth and maturation. Therefore, initiate levothyroxine sodium tablets therapy immediately upon diagnosis. Levothyroxine is generally continued for life in these patients. <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID238">5.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Closely monitor infants during the first 2 weeks of levothyroxine sodium tablets therapy for cardiac overload and arrhythmias.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
               <component>
                  <section ID="ID174">
                     <id root="cf480f45-aeb1-4e5c-b383-0e342c60bb80"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Because of the increased prevalence of cardiovascular disease among the elderly, initiate levothyroxine sodium tablets at less than the full replacement dose <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID100">2.3</linkHtml>) and Warnings and Precautions (<linkHtml href="#ID118">5.2</linkHtml>)]</content>. Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly.</paragraph>
                     </text>
                     <effectiveTime value="20240229"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID178">
               <id root="c40338fe-1614-4b18-8d7d-f2ad3f932ed4"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>The signs and symptoms of overdosage are those of hyperthyroidism <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID117">5</linkHtml>) and Adverse Reactions (<linkHtml href="#ID132">6</linkHtml>)]</content>. In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures occurred in a 3-year -old child ingesting 3.6 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium.</paragraph>
                  <paragraph>Reduce the levothyroxine sodium tablets dosage or discontinue temporarily if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient's medical status.</paragraph>
                  <paragraph>For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.</paragraph>
               </text>
               <effectiveTime value="20240314"/>
            </section>
         </component>
         <component>
            <section ID="ID180">
               <id root="eb6cf65f-83ef-4245-a0c6-83654bb9ce74"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Levothyroxine sodium tablets USP is L-thyroxine (T4) and contains synthetic crystalline L-3,3',5,5' tetraiodothyronine sodium salt. Synthetic T4 is chemically identical to that produced in the human thyroid gland. Levothyroxine (T4) sodium has an empirical formula of C<sub>15</sub>H<sub>10</sub>I<sub>4</sub>N NaO<sub>4</sub>•H<sub>2</sub>O, molecular weight of 798.85 (anhydrous), and structural formula as shown:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Levothyroxine sodium tablets USP for oral administration are supplied in the following strengths: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg. Each levothyroxine sodium tablets USP contains the inactive ingredients corn starch, croscarmellose sodium, magnesium stearate, mannitol and sodium bicarbonate. Table 9 provides a listing of the color additives by tablet strength:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 9. Levothyroxine Sodium Tablets USP Color Additives</content>
                  </paragraph>
                  <table width="638" styleCode="Noautorules">
                     <col width="211"/>
                     <col width="427"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="2">
                              <paragraph>Levothyroxine sodium tablet USP meets USP Dissolution Test 2.</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Strength (mcg)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Color additive(s)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 25<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> FD&amp;C Yellow No. 6 Aluminum Lake*<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 50<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> FD&amp;C Blue 1 Aluminum Lake<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 75<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> FD&amp;C Red No. 40 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 88<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> FD&amp;C Yellow No. 6 Aluminum Lake*, FD&amp;C Blue No. 1 Aluminum Lake, D&amp;C Yellow No. 10 Aluminum Lake<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 100<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> FD&amp;C Yellow No. 6 Aluminum Lake*, D&amp;C Yellow No. 10 Aluminum Lake<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 112<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> D&amp;C Red No. 27 Aluminum Lake<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 125<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> FD&amp;C Yellow No. 6 Aluminum Lake*, FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 137<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> FD&amp;C Blue No. 1 Aluminum Lake<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 150<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> FD&amp;C Blue No. 2 Aluminum Lake<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 175<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> FD&amp;C Blue No. 1 Aluminum Lake, D&amp;C Red No. 27 Aluminum Lake<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 200<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> FD&amp;C Red No. 40 Aluminum Lake<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 300<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> FD&amp;C Yellow No. 6 Aluminum Lake*, FD&amp;C Blue No. 1 Aluminum Lake, D&amp;C Yellow No. 10 Aluminum Lake<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left"> *Note – FD&amp;C Yellow No. 6 Aluminum Lake is peach in color.<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250319"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>image-1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="94052e3d-58b2-4f4b-8223-a47281c1a592-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID185">
               <id root="932cc479-8b49-487e-8773-f9f3c2354c6e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250319"/>
               <component>
                  <section ID="ID186">
                     <id root="c24b4ea7-731f-4a67-b54f-44e193fe2e8a"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.</paragraph>
                        <paragraph>The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.</paragraph>
                     </text>
                     <effectiveTime value="20221203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID188">
                     <id root="f0576e1c-3d59-46fb-b55c-2333a14e3945"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Oral levothyroxine sodium is a synthetic T4 hormone that exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present.</paragraph>
                     </text>
                     <effectiveTime value="20221203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID190">
                     <id root="3a080bd9-40ce-4a7c-a0a0-f7d86a1293a3"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Absorption of orally administered T4 from the gastrointestinal tract ranges from 40% to 80%. The majority of the levothyroxine sodium tablets dose is absorbed from the jejunum and upper ileum. The relative bioavailability of levothyroxine sodium tablets, compared to an equal nominal dose of oral levothyroxine sodium solution, is approximately 93%. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans. Dietary fiber decreases bioavailability of T4. Absorption may also decrease with age. In addition, many drugs and foods affect T4 absorption <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID138">7</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T4 compared to T3. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID138">7</linkHtml>)]</content>. Thyroid hormones do not readily cross the placental barrier <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID168">8.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>T4 is slowly eliminated (see Table 10). The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately 80% of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amounts of T3 and reverse T3 (rT3). T3 and rT3 are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age.</paragraph>
                        <table width="638" styleCode="Noautorules">
                           <caption>  Table 10. Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients </caption>
                           <col width="134"/>
                           <col width="135"/>
                           <col width="124"/>
                           <col width="121"/>
                           <col width="124"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph>a. Includes TBG, TBPA, and TBA</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph>b. 3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Hormone</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Ratio in Thyroglobulin</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Biologic Potency</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> t<sub>1/2</sub> (days)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Protein Binding (%)<sup>a</sup>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Levothyroxine (T4)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 10 to 20<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 1<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 6 to 7<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 99.96<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Liothyronine (T3)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 1<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ≤ 2<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> 99.5<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250319"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID193">
               <id root="5616b822-7b52-4bb2-a68d-40642c1fae3a"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20221203"/>
               <component>
                  <section ID="ID194">
                     <id root="f7566252-4032-4d19-8df4-260399b34bf8"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term carcinogenicity studies in animals to evaluate the carcinogenic potential of levothyroxine have not been performed. Studies to evaluate mutagenic potential and animal fertility have not been performed.</paragraph>
                     </text>
                     <effectiveTime value="20221203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID196">
               <id root="3aa89869-807c-415e-864d-aabaeac8f496"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Product:    50090-4947</paragraph>
                  <paragraph>NDC:    50090-4947-0   30 TABLET in a BOTTLE</paragraph>
                  <paragraph>NDC:    50090-4947-1   90 TABLET in a BOTTLE</paragraph>
               </text>
               <effectiveTime value="20250522"/>
            </section>
         </component>
         <component>
            <section ID="ID200">
               <id root="65f25992-af7e-48a1-8f4c-a3d5a2be82b2"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Inform the patient of the following information to aid in the safe and effective use of levothyroxine sodium tablets<content styleCode="italics">:</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Dosing and Administration</content>
                  </paragraph>
                  <list listType="unordered" ID="ID202" styleCode="Disc">
                     <item>Instruct patients to take levothyroxine sodium      tablets only as directed by their healthcare provider.</item>
                     <item>Instruct patients to take levothyroxine sodium      tablets as a single dose, preferably on an empty stomach, one-half to one      hour before breakfast.</item>
                     <item>Inform patients that agents such as iron and      calcium supplements and antacids can decrease the absorption of      levothyroxine. Instruct patients not to take levothyroxine sodium tablets      within 4 hours of these agents.</item>
                     <item>Instruct patients to notify their healthcare      provider if they are pregnant or breastfeeding or are thinking of becoming      pregnant while taking levothyroxine sodium tablets.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Important Information</content>
                  </paragraph>
                  <list listType="unordered" ID="ID204" styleCode="Disc">
                     <item>Inform patients that it may take several weeks before they notice an improvement in symptoms.</item>
                     <item>Inform patients that the levothyroxine in levothyroxine sodium tablet is intended to replace a hormone that is normally produced by the thyroid gland. Generally, replacement therapy is to be taken for life.</item>
                     <item>Inform patients that levothyroxine sodium tablets should not be used as a primary or adjunctive therapy in a weight control program.</item>
                     <item>Instruct patients to notify their healthcare provider if they are taking any other medications, including prescription and over-the-counter preparations.</item>
                     <item>Instruct patients to discontinue biotin or any biotin-containing supplements for at least 2 days before thyroid function testing is conducted.</item>
                     <item>Instruct patients to notify their physician of any other medical conditions they may have, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems, as the dose of medications used to control these other conditions may need to be adjusted while they are taking levothyroxine sodium tablets. If they have diabetes, instruct patients to monitor their blood and/or urinary glucose levels as directed by their physician and immediately report any changes to their physician. If patients are taking anticoagulants, their clotting status should be checked frequently.</item>
                     <item>Instruct patients to notify their physician or dentist that they are taking levothyroxine sodium tablets prior to any surgery.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Adverse Reactions</content>
                  </paragraph>
                  <list listType="unordered" ID="ID206" styleCode="Disc">
                     <item>Instruct patients to notify their healthcare      provider if they experience any of the following symptoms: rapid or      irregular heartbeat, chest pain, shortness of breath, leg cramps,      headache, nervousness, irritability, sleeplessness, tremors, change in      appetite, weight gain or loss, vomiting, diarrhea, excessive sweating,      heat intolerance, fever, changes in menstrual periods, hives or skin rash,      or any other unusual medical event.</item>
                     <item>Inform patients that partial hair      loss may occur rarely during the first few months of levothyroxine sodium      tablets therapy, but this is usually temporary.</item>
                  </list>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>Naples, FL 34108</paragraph>
                  <paragraph>United States</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Limited</content>
                  </paragraph>
                  <paragraph>Pithampur (M.P.) - 454 775</paragraph>
                  <paragraph>INDIA</paragraph>
                  <paragraph>Revised: August 2024                                                                                     ID#: 276412</paragraph>
               </text>
               <effectiveTime value="20250207"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>trade mark</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="94052e3d-58b2-4f4b-8223-a47281c1a592-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="244614ac-601c-40db-8bce-232044cc5dbf"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Levothyroxine Sodium</title>
               <text>
                  <renderMultiMedia referencedObject="lbl500904947"/>
               </text>
               <effectiveTime value="20250522"/>
               <component>
                  <observationMedia ID="lbl500904947">
                     <text>Label Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="lbl500904947.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>